R&D, Ruh-Roh

Pharmaceutical companies are watching their R&D costs go up, up, up, as they search for the next blockbuster drug amid dried-up pipelines and upcoming patent cliffs, reports The Guardian's Julia Kollewe. A recent Deloitte report shows that the cost of bringing a drug to market for the world's 12 biggest pharma companies has risen by more than 25 percent to about $1 billion this year from about $830 million in 2010, Kollewe says.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.